SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is trending as investors focus on its role in building decentralized AI infrastructure, with significant community excitement surrounding its potential as a long-term asset akin to early-stage growth plays. Discussions are heavily focused on the project's subnet ecosystem, institutional interest, and the strategy of staking as a means to accumulate value despite broader market volatility.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is attracting significant attention as community members analyze its resilience amidst geopolitical tensions and supply chain complexities while weighing the impact of its major Small Modular Reactor (SMR) contracts and defense partnerships. Investors are actively discussing the company's long-term transformation, focusing on whether current volatility provides an optimal entry point or signals broader headwinds for its commercial aerospace engine business.

Tema ETF Trust - Tema Space Innovators ETF

Tema Space Innovators ETF

The Tema Space Innovators ETF ($NASA) is experiencing high volatility as investors navigate the highly anticipated SpaceX IPO and broader sector re-rating. Community members are actively debating whether the current pullback represents a strategic buying opportunity before potential index inclusion or a liquidity-driven flush as capital rotates toward the direct SpaceX listing.

Space Exploration Technologies Corp. engages in the integrated hardware and software infrastructure of the future across space, connectivity, and AI. at core, are builders. The firm design, manufacture, launch, and operate products and services built on cutting-edge technologies, including the world’s most advanced rockets and spacecraft. It provides satellite communication services. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX's Nasdaq debut has triggered intense debate, with the stock drawing record trading volumes and massive institutional inflows despite significant concerns over its lack of profitability and sky-high valuation. While bullish investors view the company as a transformative leader in space and AI infrastructure, the community remains divided as traders focus on the upcoming options chain launch and the technical implications of its massive market capitalization.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corporation is experiencing significant volatility as investors weigh disappointing monthly sales data against anticipated long-term milestones like J-code reimbursement and potential European market expansion. The community remains deeply divided, with many shareholders dismissing the price drop as algorithmic manipulation and short-term weakness while expressing frustration over management's lack of transparency regarding recent executive departures.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

TRUMP CRYPTO is experiencing significant volatility and intense community debate as investors react to ongoing concerns about the project's long-term utility and its association with political figures. While some traders are attempting to capitalize on short-term price fluctuations, the broader community is deeply polarized, with many users openly questioning the project's transparency and citing sharp declines from historical highs as evidence of potential risks.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is experiencing significant volatility and downward pressure despite reporting strong quarterly revenue, leaving investors divided between those focused on the potential of the Elevidys gene therapy pipeline and those frustrated by a perceived lack of management action on the share price. The community is actively discussing potential leadership transitions, rumors of a strategic reorganization or buyout, and the impact of broader biotech sector headwinds on the symbol's recent performance.

Vanguard Index Funds - Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF

Vanguard Total Stock Market ETF is trending as investors grapple with escalating volatility stemming from the ongoing conflict with Iran and concerns regarding a potential regional ground incursion. The broader market sentiment is reacting to community anxiety over rising energy costs, potential inflation spikes, and the sustainability of the current AI-driven equity valuations.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as investors react to a significant patent extension securing exclusivity through 2041 and subsequent analyst price target upgrades, fueling a surge in volume and stock price to multi-year highs. The community is actively debating the implications of this news for a potential buyout while closely monitoring the status of European regulatory milestones and management's ongoing clinical development strategy.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Firefly Aerospace is seeing significant volatility and intense community discussion following the announcement of a public stock offering, which has triggered a sharp price correction despite the company recently securing a major NASA lunar contract. Investors are actively debating whether this pullback represents an attractive buying opportunity ahead of the highly anticipated SpaceX IPO or if broader sector-wide liquidity rotations and dilution concerns signal further downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?

Intellia Therapeutics (NTLA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now? 

NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets. 

Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?

NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.

NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus

Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.

Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates

Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +11.60% and -3.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates

Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -50.00% and +0.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of -438.92% and +6.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Key PointsArk Invest added to existing positions in Shopify, Intellia Therapeutics, and GeneDX on Tuesday...

NTLA Q2 EPS Increased by Brookline Capital Markets

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Stock analysts at Brookline Capital Markets upped their Q2 2026 EPS estimates for Intellia Therapeutics in a report released on Wednesday, April 29th. Brookline Capital Markets analyst L. Cann now anticipates that the company will earn ($0.75...

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

NTLAIntellia Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NTLA News